Bryan M. Dunyak

Bryan M. Dunyak

Auto-generated profile, based on publicly available information

Bryan M. Dunyak

Remix Therapeutics, Watertown, MA, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Science
Verified
Journal Article
Closed access
MRMalgorzata E. Rogalska
Malgorzata E. Rogalska
EMEstefania Mancini
Estefania Mancini
SBSophie Bonnal
Sophie Bonnal
AGAndré Gohr
André Gohr
BDBryan M. Dunyak
Bryan M. Dunyak
JVJuan Valcárcel
Juan Valcárcel
The spliceosome is the complex molecular machinery that sequentially assembles on eukaryotic messenger RNA precursors to remove introns (pre-mRNA splicing), a physiologically regulated process altered in numerous pathologies. We report transcriptome-wide analyses upon systematic knock down of 305 spliceosome components and regulators in human cancer cells and the reconstruction of functional splicing factor networks that govern different classes of alternative splicing decisions. The results disentangle intricate circuits of splicing factor cross-regulation, reveal that the precise architecture of late-assembling U4/U6.U5 tri–small nuclear ribonucleoprotein (snRNP) complexes regulates splice site pairing, and discover an unprecedented division of labor among protein components of U1 snRNP for regulating exon definition and alternative 5′ splice site selection. Thus, we provide a resource to explore physiological and pathological mechanisms of splicing regulation.

10 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
DWDavid S. White
David S. White
BDBryan M. Dunyak
Bryan M. Dunyak
FVFrédéric H. Vaillancourt
Frédéric H. Vaillancourt
AHAaron A. Hoskins
Aaron A. Hoskins
Splice site recognition is essential for defining the transcriptome. Drugs like risdiplam and branaplam change how human U1 snRNP recognizes particular 5′ splice sites (5′SS) and promote U1 snRNP binding and splicing at these locations. Despite the therapeutic potential of 5′SS modulators, the complexity of their interactions and snRNP substrates have precluded defining a mechanism for 5′SS modulation. We have determined a sequential binding mechanism for modulation of −1A bulged 5′SS by branaplam using a combination of ensemble kinetic measurements and colocalization single molecule spectroscopy (CoSMoS). Our mechanism establishes that U1-C protein binds reversibly to U1 snRNP, and branaplam binds to the U1 snRNP/U1-C complex only after it has engaged with a −1A bulged 5′SS. Obligate orders of binding and unbinding explain how reversible branaplam interactions cause formation of long-lived U1 snRNP/5′SS complexes. Branaplam targets a ribonucleoprotein, not only an RNA duplex, and its action depends on fundamental properties of 5′SS recognition.